Views: 1,420 | Downloads:
179
| Responses: 0
XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Preoperative Chemoradiation for Locally Advanced Rectal Cancer with Capecitabine 2,000 mg/m2/Day
Objective: Evaluate the efficacy and the tolerability of preoperative chemoradiation with high dose
Capecitabine.
Material and Method: Fifteen patients with locally advanced resectable rectal cancer were treated with
Capecitabine 2,000 mg/m2/day, orally 7 days/week concurrent with whole pelvic irradiation 45 Gy in 25
fractions/5 weeks. Patients underwent surgery in the following 4-6 weeks.
Results: After complete treatment, 11 patients (73%) underwent surgery. Ten patients (66%) had sphincter
preservative surgery; three of them had primary tumors located in the lower rectum. Five patients had grade
2 and one patient had grade 3 diarrhea. No grade 4 toxicity was reported.
Conclusion: Preoperative Capecitabine 2,000 mg/m2/day concurrent with whole pelvic irradiation were
effective and well tolerated. The potential dose limiting toxicity effect was the diarrhea.
Keywords: Rectal cancer, Chemoradiation, Capecitabine, Radiotherapy
Capecitabine.
Material and Method: Fifteen patients with locally advanced resectable rectal cancer were treated with
Capecitabine 2,000 mg/m2/day, orally 7 days/week concurrent with whole pelvic irradiation 45 Gy in 25
fractions/5 weeks. Patients underwent surgery in the following 4-6 weeks.
Results: After complete treatment, 11 patients (73%) underwent surgery. Ten patients (66%) had sphincter
preservative surgery; three of them had primary tumors located in the lower rectum. Five patients had grade
2 and one patient had grade 3 diarrhea. No grade 4 toxicity was reported.
Conclusion: Preoperative Capecitabine 2,000 mg/m2/day concurrent with whole pelvic irradiation were
effective and well tolerated. The potential dose limiting toxicity effect was the diarrhea.
Keywords: Rectal cancer, Chemoradiation, Capecitabine, Radiotherapy
Download:
PDF